These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
263 related articles for article (PubMed ID: 23673229)
1. Combined screening for open spina bifida at 11-13 weeks using fetal biparietal diameter and maternal serum markers. Bernard JP; Cuckle HS; Bernard MA; Brochet C; Salomon LJ; Ville Y Am J Obstet Gynecol; 2013 Sep; 209(3):223.e1-5. PubMed ID: 23673229 [TBL] [Abstract][Full Text] [Related]
2. Biparietal diameter at 11-13 weeks' gestation in fetuses with open spina bifida. Khalil A; Coates A; Papageorghiou A; Bhide A; Thilaganathan B Ultrasound Obstet Gynecol; 2013 Oct; 42(4):409-15. PubMed ID: 23362051 [TBL] [Abstract][Full Text] [Related]
3. First trimester maternal serum alpha-fetoprotein is not raised in pregnancies with open spina bifida. Spencer K; Khalil A; Brown L; Mills I; Horne H Prenat Diagn; 2014 Feb; 34(2):168-71. PubMed ID: 24226839 [TBL] [Abstract][Full Text] [Related]
4. Biparietal/transverse abdominal diameter ratio ≤ 1: potential marker for open spina bifida at 11-13-week scan. Simon EG; Arthuis CJ; Haddad G; Bertrand P; Perrotin F Ultrasound Obstet Gynecol; 2015 Mar; 45(3):267-72. PubMed ID: 24817098 [TBL] [Abstract][Full Text] [Related]
6. The role of maternal serum α-fetoprotein in screening for open spina bifida at 11-13 weeks. Spencer K Am J Obstet Gynecol; 2014 Feb; 210(2):172. PubMed ID: 23994744 [No Abstract] [Full Text] [Related]
7. Maternal serum biochemistry at 11-13(+6) weeks in relation to the presence or absence of the fetal nasal bone on ultrasonography in chromosomally abnormal fetuses: an updated analysis of integrated ultrasound and biochemical screening. Cicero S; Spencer K; Avgidou K; Faiola S; Nicolaides KH Prenat Diagn; 2005 Nov; 25(11):977-83. PubMed ID: 16245371 [TBL] [Abstract][Full Text] [Related]
8. Co-variables in first trimester maternal serum screening. de Graaf IM; Cuckle HS; Pajkrt E; Leschot NJ; Bleker OP; van Lith JM Prenat Diagn; 2000 Mar; 20(3):186-9. PubMed ID: 10719318 [TBL] [Abstract][Full Text] [Related]
9. First trimester screening for Down syndrome using nuchal translucency, maternal serum pregnancy-associated plasma protein A, free-β human chorionic gonadotrophin, placental growth factor, and α-fetoprotein. Huang T; Dennis A; Meschino WS; Rashid S; Mak-Tam E; Cuckle H Prenat Diagn; 2015 Jul; 35(7):709-16. PubMed ID: 25846403 [TBL] [Abstract][Full Text] [Related]
10. ADAM 12 as a first-trimester maternal serum marker in screening for Down syndrome. Laigaard J; Spencer K; Christiansen M; Cowans NJ; Larsen SO; Pedersen BN; Wewer UM Prenat Diagn; 2006 Oct; 26(10):973-9. PubMed ID: 16892462 [TBL] [Abstract][Full Text] [Related]
11. Amniotic-fluid alpha-fetoprotein measurement in antenatal diagnosis of anencephaly and open spina bifida in early pregnancy. Second report of the U.K. Collaborative Study on Alpha-fetoprotein in Relation to Neural-tube Defects. Lancet; 1979 Sep; 2(8144):651-62. PubMed ID: 90757 [TBL] [Abstract][Full Text] [Related]
12. A screening program for trisomy 21 at 10-14 weeks using fetal nuchal translucency, maternal serum free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A. Spencer K; Souter V; Tul N; Snijders R; Nicolaides KH Ultrasound Obstet Gynecol; 1999 Apr; 13(4):231-7. PubMed ID: 10341399 [TBL] [Abstract][Full Text] [Related]
15. Maternal serum hyperglycosylated human chorionic gonadotrophin (HhCG) in the first trimester of pregnancies affected by Down syndrome, using a sialic acid-specific lectin immunoassay. Spencer K; Talbot JA; Abushoufa RA Prenat Diagn; 2002 Aug; 22(8):656-62. PubMed ID: 12210572 [TBL] [Abstract][Full Text] [Related]
16. Combined measurement of fetal nuchal translucency, maternal serum free beta-hCG, and pregnancy-associated plasma protein A for first-trimester Down's syndrome screening. Tsai MS; Huang YY; Hwa KY; Cheng CC; Lee FK J Formos Med Assoc; 2001 May; 100(5):319-25. PubMed ID: 11432311 [TBL] [Abstract][Full Text] [Related]